From IHUB’s falconer66a, Fletch falconer66a

New Post Public Reply Private Reply Replies (1) Message Board
fletch Drano #1036
813
From IHUB’s falconer66a,
Fletch

falconer66a Thursday, 06/04/20 02:41:21 PM
Re: None 0
Post # of 253611
Hope this is acceptable:

The superiority of Anavex against the other Alzheimer's treatments needs to be understood.

Ok, a new candidate drug is going to solve the Alzheimer’s problem, not by focusing on amyloid plaques or tau tangles, but by, somehow, improving the function of synapses (contact points between neurons).

Parties “are backing a drug — NDX-1017 — that bypasses the whole toxic plaque debate and focuses on another familiar strategy: the frayed synaptic network in the brain that erodes with the disease. Boost the network and you can stop, possibly reverse, the damage that corrodes cognition. For awhile.”

Well and good — if positive results appear with this new drug. But since the drug in no way addresses root causes of Alzheimer’s, which is the pathogenic non-clearance of wastes in neurons and nerves (the amyloid and tau proteins) those will continue to accumulate.

Understand, all sorts of potentially toxic wastes are continually produced by living cells, tissues, and organisms. Think not? Then don’t use a toilet for 24 hours; see how that works out.

This is where the mechanisms of action (MOA) of the Anavex sigma-1 receptor agonists separate themselves from all the other Alzheimer’s treatment approaches. Each of them (there are but a few), as with this new proposed drug, try to reduce only symptoms. For a period, this, to a degree, can happen. But sooner or later (usually sooner) the biochemical mechanisms of symptomatic suppression are overwhelmed. Fatal.

The real problem is the inability of neurons and nerves with Alzheimer’s to efficiently clear the biochemical wastes, before they can pathogenically accumulate. Here’s an analogy.

Your furnace, in winter, produces toxic waste gases, including carbon dioxide and carbon monoxide. Your furnace, normally and properly, voids these wastes out of the chimney. Well and good.

But how do you “treat” your furnace if a carbon monoxide sensor in your hallway goes off? “Whoa, something’s wrong.” Carbon monoxide is both odorless and fatal (in high concentrations). So, you turn off your furnace, and call the HVAC contractor to fix the problem.

But you could have dealt with it like the current Alzheimer’s drugs do. Treat the symptoms, not the causes of them. Very simple. Just open the windows to allow enough fresh air into the room so as to sufficiently dilute the carbon monoxide. That would work, would it not? Well, until it got really cold.

The solution to both problems, Alzheimer’s and a furnace leaking carbon monoxide into the heating airstreams of a house, is to fix the root cause. In the case of the furnace, find the corroded gap in the fire chamber, and replace it with a new one (or, an entire new furnace). Problem solved.

In the case of Alzheimer’s, biochemically arrange for the restoration of the normalized clearance of wastes. With that, Alzheimer’s is impossible. No pathological accumulation of wastes; neither beta-amyloids or tau tangles. Nerves function normally.

How, then, is this arranged? But ingesting (orally) small amounts of blarcamesine, AKA Anavex 2-73. By its activation of the sigma-1 receptor protein (among other things) this proprietary molecule allows the cell to resume normalized function. “Homeostasis” (feedback-controlled cell processes) is restored. Wastes cannot accumulate. Before they do, their increasing concentration is detected by the cell which, then, turns on increased waste-clearance processes (the cell uses the toilet frequently, as it were).

Essential to all homeostatic processes (and many others) in the cell (especially with age) is the proper folding of proteins into fully functioning enzymes. Blarcamesine causes this. With that, wastes can be enzymatically rendered and compartmentalized into waste-clearing structures before they are pathogenic. Problem solved.

Anavex solves the Alzheimer’s problem at the top, at the start of the cascade of processes that result in the disease. All of the other treatment approaches deal, ever so inadequately or briefly, with only “downstream” factors. The problems continue.

Anavex is way better.

https://investorshub.advfn.com/boards/read_ms...=156058332

Anavex Life Sciences Corp. (AVXL) Stock Research Links

AVXL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 107

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 44

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 45

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 66

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 74

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 55

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 44

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 166

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 173

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading

Top 5 Most Recently Viewed Articles

Ethyl Alcohol Market Poised for Growth Amid AI Innovations

Updated Category News Views 195

Ethyl Alcohol Market Growth Fueled by AI Innovations The ethyl alcohol market is on the brink of significant growth as industries worldwide evolve. Recent trends suggest a promising expansion, with an expected increase of USD 16.94 billion from 2024 to 2028, based on insightful reports. This upward trajectory will stem from several key factors, such as an ample supply of...

Continue Reading
Meghan's Exciting Gourmet Brand Launch: A New Era Begins

Updated Category News Views 344

Meghan, Duchess of Sussex, Launches Gourmet Brand In a fresh and exciting venture, Meghan, Duchess of Sussex, proudly presents her new brand, As Ever. This lifestyle brand focuses on offering beautifully crafted gourmet products meant to enhance daily living. Known for her commitment to quality and authenticity, Meghan has partnered with skilled artisans to ensure each...

Continue Reading
Osisko Development Completes US$24.2 Million Private Placement

Updated Category News Views 64

Osisko Development Corp. hit a key funding milestone back in 2024 when it pulled together around US$24.2 million through a non-brokered private placement. This wasn’t just another run-of-the-mill financing—traders were watching closely as Osisko’s ambitious plans for the gold sector began to take shape. Private Placement Breakdown: What You Need to Know The first...

Continue Reading
Tesla's Stock Adjustment: Analyst Insights on AI and Valuation

Updated Category News Views 261

Tesla Faces New Analyst Ratings Amid Market Dynamics Tesla Inc. shares have seen a downward shift recently due to a change in rating from a prominent investment bank. Following Morgan Stanley's latest assessment, the stock's rating transitioned from Overweight to Equal-Weight. This reevaluation stems from concerns surrounding valuation, as new lead analyst Andrew Percoco...

Continue Reading
FTAI Aviation Ltd. Announces Strong Q3 2025 Performance Review

Updated Category News Views 328

FTAI Aviation Ltd. Financial Highlights for Q3 2025 FTAI Aviation Ltd. (NASDAQ: FTAI) revealed its financial results for the third quarter of 2025, demonstrating significant growth and profitability during this period. The company's net income attributable to shareholders reached a remarkable $114 million, which translates to an earnings per share (EPS) of $1.11, marking...

Continue Reading